Advertisement
No AccessJournal of UrologyAdult Urology1 Feb 2014

Impact of Preoperative Anemia on Oncologic Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy

    View All Author Information

    Purpose:

    We evaluated the impact of preoperative anemia on oncologic outcomes in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.

    Materials and Methods:

    A total of 282 patients with upper tract urothelial carcinoma underwent radical nephroureterectomy. Preoperatively measured hemoglobin values were stratified into normal and anemia based on the WHO classification of 13 gm/dl or less and 12 or less considered anemia in males and females, respectively. We performed sensitivity analysis based on contemporary anemia classifications adjusted for the impact of age, gender and race with anemia considered a hemoglobin value of 13.7 gm/dl or less and 13.2 or less in white males younger than 60 and 60 years old or older, respectively, and 12.2 gm/dl or less in white females of all ages. Univariable and multivariable Cox regression analyses were done to assess the effects of anemia on oncologic outcomes.

    Results:

    Median preoperative hemoglobin was 13.2 gm/dl (IQR 11.7, 14.3). A total of 112 patients (39.7%) were anemic by the WHO classification vs 129 (45.7%) by the contemporary classification. Anemia was associated with lymph node metastasis, lymphovascular invasion, sessile tumor architecture, tumor necrosis, advanced age and a higher ECOG (Eastern Cooperative Oncology Group) performance score using the WHO and/or the contemporary definition (p ≤0.044). At a median 30-month followup anemia was associated with decreased recurrence-free (p ≤0.008) and cancer specific (p <0.001) survival on Kaplan-Meier analyses. On multivariable analysis adjusted for standard clinicopathological factors anemia remained an independent predictor of disease recurrence (HR 1.76, 95% CI 1.17–2.63 and 1.89, 95% CI 1.26–2.86) and cancer specific mortality (HR 1.88, 95% CI 1.15–3.08 and 2.04, 95% CI 1.21–3.45) by the WHO and contemporary classifications, respectively.

    Conclusions:

    Preoperative anemia is an independent predictor of disease recurrence and cancer specific mortality. It is associated with aggressive tumor features in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. Hemoglobin is a promising marker for patient counseling and risk stratification for additional treatment decision making.

    References

    • 1 : Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer2009; 115: 1224. Google Scholar
    • 2 : Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol2012; 19: 4337. Google Scholar
    • 3 : European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol2011; 59: 584. Google Scholar
    • 4 : Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int2011; 107: 1059. Google Scholar
    • 5 : Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep2012; 13: 122. Google Scholar
    • 6 : Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol2003; 47: 1. Google Scholar
    • 7 : The prognostic value of pre-operative parameters in patients undergoing radical cystectomy for bladder cancer. J Urol2013; 189: e584. AbstractGoogle Scholar
    • 8 : The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study. Eur Urol2012; . Epub ahead of print. Google Scholar
    • 9 : The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol2012; 61: 245. Google Scholar
    • 10 : Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol2012; 188: 398. LinkGoogle Scholar
    • 11 : The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed?. Eur Urol2009; 56: 512. Google Scholar
    • 12 : Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol2012; 62: 677. Google Scholar
    • 13 : American Joint Committee on Cancer (AJCC) Staging Manual. New York: Springer2010. Google Scholar
    • 14 : The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol1998; 22: 1435. Google Scholar
    • 15 : Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int2009; 103: 307. Google Scholar
    • 16 : Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol2010; 57: 575. Google Scholar
    • 17 : Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol2009; 27: 612. Google Scholar
    • 18 : Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol2012; 61: 854. Google Scholar
    • 19 Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser1968; 405: 5. Google Scholar
    • 20 : The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?. Blood2006; 107: 1747. Google Scholar
    • 21 : Evaluating the yield of medical tests. JAMA1982; 247: 2543. Google Scholar
    • 22 : Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med1996; 15: 361. Google Scholar
    • 23 : Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol2001; 54: 774. Google Scholar
    • 24 : Challenges of cancer biomarker profiling. Eur Urol2007; 52: 1601. Google Scholar
    • 25 Birgegard G, Aapro MS, Bokemeyer C et al: Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology, suppl., 2005; 68: 3. Google Scholar
    • 26 : Hyperoxia-induced improvement of the in vitro response to gemcitabine in transitional cell carcinoma. Anticancer Res2005; 25: 3413. Google Scholar
    • 27 Sabbatini P: The relationship between anemia and quality of life in cancer patients. Oncologist, suppl., 2000; 5: 19. Google Scholar
    • 28 : Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev2000; 26: 303. Google Scholar
    • 29 : Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int2013; 112: 453. Google Scholar
    • 30 : The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol2013; 63: 839. Google Scholar
    Advertisement